Sobi publishes Q4 and FY 2021 report

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announces its results for the fourth quarter and full year of 2021.

October – December 2021

• Total revenue SEK 4,896 M (4,581), +7 per cent, +9 per cent at constant exchange rates (CER)
• Haematology revenue SEK 2,242 M (2,081), +8 per cent at CER of which Elocta® SEK 1,063 M (1,071), unchanged at CER, Alprolix® SEK 482 M (419), +16 per cent at CER, and Doptelet® SEK 306 M (191), +60 per cent at CER. First shipment of Empaveli™ achieved
• Immunology revenue SEK 2,330 M (2,281), +6 per cent at CER of which Kineret® SEK 682 M (586), +16 per cent at CER, Synagis® SEK 1,364 M (1,432), +1 per cent at CER, and Gamifant® SEK 284 M (263), +10 per cent at CER
• EBITA¹ SEK 2,002 M (2,576), EBITA margin¹ 41 per cent (56, adjusted 48)
• Earnings per share (EPS) before dilution SEK 4.21 (5.09)
• Cash flow from operating activities SEK 2,121 M (716)
• Aspaveli® EU approval and Kineret EU approval extension

January – December 2021

• Total revenue SEK 15,529 M (15,261), +2 per cent, +7 per cent at CER
• Haematology revenue SEK 8,536 M (8,660), +3 per cent at CER of which Elocta SEK 3,960 M (4,585), -11 per cent at CER, Alprolix SEK 1,764 M (1,705), +7 per cent at CER, and Doptelet SEK 1,116 M (587), +104 per cent at CER
• Immunology revenue SEK 5,780 M (5,415), +15 per cent at CER of which Kineret SEK 2,290 M (2,079), +16 per cent at CER, Synagis SEK 2,650 M (2,726), +6 per cent at CER, and Gamifant SEK 840 M (609), +48 per cent at CER
• EBITA¹ SEK 5,575 M (6,700), EBITA margin¹ 36 per cent (44, adjusted 41)
• EPS before dilution SEK 9.08 (11.01)
• Cash flow from operating activities SEK 5,470 M (4,926)

2022 outlook

• Revenue is anticipated to grow by a mid to high single-digit percentage at CER
• EBITA margin is anticipated to be at a low 30s percentage of revenue

Financial summary

Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session at 12:00 CET. The event will in English.

The presentation can be followed live or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.

To participate in the conference call, please call:

Sweden: +46 8 505 583 73 (direct)

UK: +44 3 333 009 272 (direct)

US: +1 631 913 14 22 (toll) PIN: 50558397#

Sobi®
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East and Asia. In 2021, revenue amounted to SEK 15.5 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com, LinkedIn and YouTube.

This information is information that Swedish Orphan Biovitrum AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CET on 10 February 2022.

Contacts

Thomas Kudsk Larsen
Head of Communication and Investor Relations

Maria Kruse
Director of Communication and Investor Relations

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.